Physician profile
Bethany King
NPI 1346980976
$668.06
in general payments reported to CMS, 2019-2025
11 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.71 · 2023: $99.73 · 2024: $390 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.62 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.98 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $103.08 | 2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $80.62 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $65.38 | 2025 | |
| Abbvie INC. | $39.32 | 2024-2025 | |
| Lilly USA, LLC | $31.99 | 2022-2023 | Jardiance, Lyumjev, Baqsimi |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $19.88 | 2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $17.68 | 2025 | Farxiga |
| Ucb, INC. | $17.52 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.